Trial Profile
A Phase I/II Study of Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 06 May 2022 Status changed from active, no longer recruiting to discontinued.
- 22 Feb 2022 Planned End Date changed from 31 Dec 2029 to 31 Mar 2022.
- 22 Feb 2022 Planned primary completion date changed from 31 Dec 2029 to 31 Mar 2022.